230 results about "Specific protein" patented technology

The invention relates to the technical field of bioactive peptides, in particular to a novel multifunctional collagen-like tripeptide and application thereof, an amino acid sequence contains multiple combinations, X can be selected from multiple components, 3-methoxy-4-hydroxyphenylalanine and the like are added, and the novel multifunctional collagen-like tripeptide can interact with specific proteins, activate related pathways and play multiple physiological functions and is applied to multiple fields. The collagen-like tripeptide has obvious advantages, innovates component expansion functions, improves the preparation method, improves the efficiency, reduces the cost, is matched with other components in the fields of beauty, health care and medicine, enhances the efficacy, realizes targeted delivery, and brings a new opportunity to related industries.

The invention relates to a UGT enzyme subtype substrate specificity prediction method and model. On the basis of a directional message passing neural network, graph structure characterization of a small molecule compound and features of specific protein binding sites of UGT enzyme are deeply fused, a bimodal prediction normal form of'molecule + protein binding sites' is designed, a deep learning model is constructed, conversion from compound center prediction to molecule-enzyme binding site comprehensive prediction is achieved, and the prediction accuracy is improved. And accurate classification prediction can be carried out on UGT enzyme substrates and non-substrates.

The invention relates to a urine specific protein detection sample quality screening system and screening method. The screening method comprises the following steps: firstly, creating a urine specific protein quality model; then collecting an image of a to-be-detected sample; and finally, analyzing and evaluating the sample to be detected according to the sample quality model and the image of the sample to be detected, and converting urine colors (such as light yellow, deep yellow, hematuria and the like) into quantifiable numerical values by collecting the image of the sample (urine). Compared with traditional naked eye observation, judgment deviation caused by subjective factors such as experience and ambient light of detection personnel is avoided, and the detection result is more objective and repeatable; according to the method, the sample image is converted into quantifiable numerical values so as to carry out numerical analysis on the detection data of the color, clarity and turbidity of the sample, hematuria and urine with high turbidity in the sample are automatically screened out, manual operation steps are reduced, the detection efficiency is improved, and the method is particularly suitable for clinical or large-scale screening scenes.

The utility model discloses a novel protein marker diagnostic kit for detecting the muscle injury degree, which comprises a detection kit for detecting the muscle injury degree and a dustproof cover assembled above the detection kit, the detection kit is provided with a detection port for dropping blood of a patient and a display port for displaying a diagnosis result, a reagent card for evaluating the muscle injury degree by detecting the concentration of a specific protein marker in the blood is arranged in the detection kit, and the detection end of the reagent card is located below the detection port. The display end of the reagent card is positioned below the display opening; a positioning opening for positioning the dustproof cover is formed above the detection kit, and a positioning block matched with the positioning opening is arranged in the dustproof cover. According to the utility model, the muscle injury degree of a patient can be detected by quickly reading the novel protein marker in the blood, so that an accurate diagnosis and treatment basis is provided for the treatment of the patient, the detection time of the patient is shortened, and the treatment cost is reduced.

The invention is applicable to the technical field of vaccines, and provides a haemaphysalis unguiculata salivary gland multi-component subunit vaccine as well as a preparation method and application thereof, the effective components of the vaccine comprise rHlPDI-2 and rHlPrx soluble recombinant proteins, and the amino acid sequences of the rHlPDI-2 and rHlPrx soluble recombinant proteins are shown as SEQ ID NO.1-2. Starting from salivary gland secretory protein related to tick activity in a host biting process of haemaphysalis unguiculata, special protein of salivary glands of tick species is researched, the recombinant protein vaccine is prepared, survival and reproduction of haemaphysalis unguiculata can be affected, and the prepared multi-component subunit vaccine has an interference effect on biting and passage of haemaphysalis unguiculata and can be used for preparing the multi-component subunit vaccine for preventing and treating haemaphysalis unguiculata. The anti-tick vaccine has a good anti-tick effect, contributes to prevention and treatment of tick-borne diseases, and lays a foundation for development of other tick related vaccines.

The invention discloses preparation and application of grouper enterospora sporowall protein SWP26 and a polyclonal antibody of the grouper enterospora sporowall protein SWP26, and belongs to the field of animal quarantine, the grouper enterospora sporowall protein SWP26 is obtained by amplifying grouper enterospora genes by using a PCR (Polymerase Chain Reaction) method, shearing a target band and transferring the target band into a pET-32a vector to construct a recombinant plasmid, and then transforming escherichia coli BL21 (DE3) for induced expression. A Ni-NTA affinity chromatography method is used for protein purification, animal immunization and polyclonal antibody purification are carried out on the purified SWP26 recombinant protein, western blot detection is carried out on the purified antibody, an obvious signal appears at about 43kDa, and it is proved that the anti-SWP26 polyclonal antibody can be subjected to a specific reaction with the SWP26 purified protein. The invention clones and identifies the high-abundance spore wall protein SWP26 positioned on the surface of the enterosporidium of the grouper for the first time, belongs to a specific protein of the enterosporidium of the grouper, and can be used as a drug target for treating enterocytozoonosis of the grouper.

The invention relates to the technical field of sample analysis, and discloses a specific protein detection method based on double-angle scattering turbidimetry, which comprises the following steps: S1, obtaining a small-angle signal concentration relation curve and a medium-angle signal concentration relation curve, and obtaining a cross threshold signal; s2, the laser light source irradiates the reaction cup from one side of the reaction cup along the horizontal axis, the detection module is located on the other side of the reaction cup and opposite to the laser light source, and the detection module collects small-angle and medium-angle scattering signals at the same time and transmits collected scattering signal information to the control module; and S3, the control module compares the received medium-angle scattering signal information with the cross threshold signal information, dynamically selects and adopts a small-angle scattering signal, and obtains the concentration of the specific protein to be detected according to a small-angle signal concentration relation formula. Or obtaining the concentration of the specific protein to be detected by adopting the medium-angle scattering signal according to a medium-angle signal concentration relation formula. The method can improve the accuracy of protein concentration analysis.

The disclosed systems and methods involve the semi-quantitative detection of disease-specific protein signatures in biological samples. The system may include a housing with a motor driven substrate holder on rails. The substrate holder is configured to be positioned at multiple locations along the guide rails. Imaging sensors capture images of portions of the substrate at these locations. The system detects markers on the substrate and determines the location of wells based on these markers. Based on the determined location of the wells, color values for each pixel in the wells can be measured. These values may be analyzed to detect disease-specific protein signatures in a variety of sample types.

The invention relates to the technical field of medical instruments, in particular to a specific protein analysis system. The system comprises a sample management device, a sample conveying device and a protein analysis device, the sample management device is used for storing a plurality of sample racks and conveying a target sample rack to a waiting station; the sample conveying device is used for conveying the target sample frame at the waiting station to the sampling station and conveying the target sample frame at the sampling station back to the waiting station; and the protein analysis device is used for collecting sample liquid from the target sample rack at the sampling station and mixing the sample liquid with a reaction reagent to realize specific protein analysis. Manual operation can be avoided, the detection efficiency can be improved, and the accuracy of a detection result can be ensured.

The present invention relates to a modified mitochondrial comprising, on the outer membrane of the mitochondrial, an antibody that binds to a cancer cell-specific protein and a cytosine deaminase. It is proved that when the mitochondria and 5-FC are jointly used for treating a pancreatic cancer cell line, the cytotoxicity induced by 5-FC treatment is remarkably enhanced. The effect is proved as follows: 5-FC is converted into 5-FU by cytosine deaminase expressed on a mitochondrial outer membrane, so that pancreatic cancer cells are induced to generate apoptosis. Therefore, the modified mitochondria according to the present invention can be effectively used in anticancer therapy using 5-FC as an anticancer agent.

The invention relates to a binding protein B capable of binding with klebsiella pneumoniae and application of the binding protein B, and belongs to the technical field of molecular biology and protein engineering. The binding protein B provided by the invention can be specifically bound with an extramembrane part of a specific protein P24017. OMPAKLEPN of klebsiella pneumoniae, and experiments such as bimolecular fluorescence complementation and flow cytometry prove that the binding protein B has good recognition and stable binding capacity on the klebsiella pneumoniae, can be used for identifying and screening the klebsiella pneumoniae, and has good application prospects. And a key tool is provided for targeted drug development aiming at the bacterium.

The application discloses a Campylobacter-specific protein antibody, an antibody-coupled magnetic bead and application. The antibody is a monoclonal antibody 1A10 and a monoclonal antibody 3D9, the monoclonal antibody 1A10 comprises a light chain variable region and a heavy chain variable region, the amino acid sequences of the light chain variable region and the heavy chain variable region of the monoclonal antibody 1A10 are shown in SEQ ID NO: 7 and 8 respectively; the monoclonal antibody 3D9 comprises a light chain variable region and a heavy chain variable region, the amino acid sequences of the light chain variable region and the heavy chain variable region of the monoclonal antibody 3D9 are shown in SEQ ID NO: 9 and 10 respectively. The antibody-coupled magnetic bead is coupled by the monoclonal antibody 1A10, the monoclonal antibody 3D9 and activated carboxyl magnetic beads respectively. The antibody-coupled magnetic bead can specifically enrich Campylobacter, has high enrichment efficiency, simple enrichment operation, can be applied to metabolic product analysis of Campylobacter, and can be used for qualitative and quantitative analysis of the Campylobacter.

Single-cell multi-omics by co-encapsulating a single cell with two beads, the first an RNA barcoding bead having barcoded mRNA capture primer oligonucleotides attached on the bead surface; and the second a DNA barcoding bead having two types of oligonucleotides releasably attached to the surface: (1) barcoded adapter oligonucleotides that are complementary to oligonucleotides bound to the transposase that are eventually incorporated into gDNA fragments and (2) polyadenylated barcoded oligonucleotides containing the same barcode sequence as the adapters. In addition, integrated analysis of RNA and protein, including intracellular protein, from individual cells using similar co-encapsulation of a single cell, an RNA barcoding bead, and with / without a specific or non-specific protein binding bead in a microwell, to avoid protein fixation by first lysing the cell to liberate intracellular contents, and then capturing protein either on a solid surface or in solution with barcoded affinity reagents.

This invention discloses an antibody targeting a specific protein of *Lactobacillus* and its applications. The monoclonal antibody of this invention is any one of monoclonal antibody 1B3, monoclonal antibody 3B5, monoclonal antibody 2E5, and monoclonal antibody 3D8, which respectively recognize proteins Srt A, Cps C, ENO 1, and Fts Z. The magnetic bead antibody conjugate is prepared by conjugating the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody conjugate of this invention can specifically enrich *Lactobacillus* bacteria with high enrichment efficiency and simple operation. It can be applied to the identification of metabolites of *Lactobacillus* bacteria, as well as their qualitative and quantitative analysis.

The application provides a kind of liposome that can enhance organ targeting, preparation method and application, belongs to the field of biological medicine and nanotechnology.The application first proposes the strategy of actively regulating LNP organ targeting by pre-assembling specific protein crown in vitro, which breaks through the technical limitations of traditional passive formation of natural protein crown.Through selecting main lipids (CDO, CDA, EDM) with different head chemical structures, precise control of protein crown composition is realized.Furthermore, the method of the application is simple in process and mild in condition, only needs standard in vitro incubation steps, and has great clinical transformation potential.The pre-assembled protein crown method provided by the application significantly enhances the organ targeting efficiency of LNP: after pre-incubation of LNP1 with APOA1, the enrichment degree of spleen is increased by 2.8 times;after pre-incubation of LNP2 with VTN, the enrichment degree of lung is increased by 52%;after pre-incubation of LNP3 with APOE, the enrichment degree of liver is increased by 1.2 times.

The invention discloses a compound for targeted ubiquitination degradation of USP7 protein, and a medicinal composition and application thereof. The structural formula of the E3 ubiquitin ligase complex is as shown in formula I. A is a specific protein ligand in the E3 ubiquitin ligase complex; l is a bivalent linking group between a USP7 protein small molecule ligand and a specific protein ligand in an E3 ubiquitin ligase complex. The protein degradation chimera has the activity of inhibiting USP7 protein and the activity of degrading USP7 protein, and can effectively inhibit malignant proliferation of acute lymphatic leukemia cells, so that the protein degradation chimera can be used for related diseases with abnormal expression of USP7 protein.

This invention discloses a multifunctional tumor-targeted cryotherapy nanoplatform and its applications, belonging to the field of nanobiomedicine technology. The multifunctional tumor-targeted cryotherapy nanoplatform of this invention uses two-dimensional Ti3C2 nanomaterials as a carrier, loaded with indocyanine green as a photosensitizer, surface-modified with polydopamine to improve stability, and loaded with gambogeylic acid as an anti-tumor drug and a heat shock protein inhibitor. It is covalently coupled with nucleic acid aptamers that can recognize cell surface-specific proteins. The multifunctional tumor-targeted cryotherapy nanoplatform has small particle size, high dispersion, and good biocompatibility, and exhibits excellent photothermal conversion ability, photodynamic therapy effect, and chemotherapy effect in tumor-targeted therapy. It can effectively induce tumor cell apoptosis under relatively low temperature conditions, significantly reducing the damage of high temperature to surrounding healthy tissues. It also has the ability to specifically recognize tumor lesions, achieving high enrichment at the tumor site and enhancing the therapeutic effect.

In vitro method for predicting mortality risk in patients suffering from shock. The present invention refers to the medical field. Particularly, it refers to an in vitro method for predicting mortality risk among patients suffering from shock, which comprises determining in a biological sample obtained from the patient the concentration level of specific proteins.

This invention discloses an antibody against a specific protein of *E. rectum*, a magnetic bead antibody-conjugate, and their applications. The monoclonal antibody is either monoclonal antibody 4D3F6H7 or monoclonal antibody 5C8E7D6. The amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 4D3F6H7 are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively. The amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 5C8E7D6 are shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively. The magnetic bead antibody-conjugate is obtained by conjugating the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody-conjugate of this invention can specifically enrich *E. rectum* with high enrichment efficiency and simple operation. It can be applied to the identification of *E. rectum* metabolites, as well as their qualitative and quantitative analysis.

This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and / or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and / or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and / or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and / or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er) / reduced tendency to give rise to such protein interference or such a signal; modified and / or improved ISV's that have no or a low(er) / reduced tendency to give rise to such protein interference or such a signal.

This invention belongs to the field of biotechnology and discloses a nucleic acid aptamer that specifically recognizes placental-specific protein 1 and its uses. The nucleotide sequence of the nucleic acid aptamer includes any one of the sequences shown in SEQ ID No. 1-57. This invention employs X-aptamer screening technology, combined with high-throughput sequencing technology and bioinformatics analysis, to reduce the number of screening rounds and obtain candidate nucleic acid aptamers. Further analysis of their affinity and specificity yields a nucleic acid aptamer that specifically recognizes placental-specific protein 1. The nucleic acid aptamer of this invention has the characteristics of high affinity and specificity, good stability, convenient synthesis, and easy labeling of functional groups. It can be used for the detection or binding of placental-specific protein 1, the diagnosis of placental-specific protein 1-related diseases, and the preparation of products for prognosis.

The present application relates to a kind of protein and its application in intestinal flora magnetic resonance imaging positioning and tracking.The amino acid sequence of the protein includes the sequence shown in SEQ ID NO.1.The present application designs specific protein, the protein can be combined with endogenous manganese ion, and effectively enhance MRI signal, express in intestinal flora, can be used endogenous manganese ion to carry out magnetic resonance imaging, realize high-resolution positioning and dynamic tracking of intestinal flora, can avoid using exogenous contrast agent, no side effect or immune response, and can be non-invasive, real-time dynamic, high-resolution imaging, provide the spatial distribution and dynamic change information of intestinal flora.

The invention discloses an SNP (Single Nucleotide Polymorphism) site related to thousand seed weight character of brassica napus and a KASP (Keyhole Associated Specific Protein) marker primer group thereof, and belongs to the field of gene engineering, the SNP marker is positioned at the 3967014bp position of the A09 chromosome of brassica napus, the reference genome version is ZS11.v0, the SNP marker has G / A polymorphism, A is an excellent allele type, the phenotype contribution rate of the A to thousand seed weight is 10.0-12.8%, and the KASP marker primer group has the advantages that the KASP marker primer group can be used for detecting the thousand seed weight character of the brassica napus; the individual with the genotype AA or AG at the position has a higher thousand seed weight character than the individual with GG. A specific KASP marker primer group is developed aiming at the SNP locus, and the KASP marker primer group can realize genetic typing of the locus, and can be used for molecular marker-assisted breeding selection, acceleration of thousand seed weight character identification and breeding in the rape breeding process, and improvement of breeding screening efficiency.

This invention relates to the field of chemiluminescence detection technology for in vitro diagnostic reagents, specifically to an S100-β chemiluminescence detection kit and its preparation method. It provides a chemiluminescence detection kit for central nervous system-specific proteins using magnetic microparticles. The kit comprises: S100-β calibrator, S100-β monoclonal antibody conjugated with carboxyl magnetic beads, S100-β monoclonal antibody labeled with alkaline phosphatase, AMPPD chemiluminescence substrate solution acted upon by alkaline phosphatase, and concentrated washing buffer. This kit achieves the following: no sample pretreatment required, easy operation, high automation, high sensitivity, automatic result output in 16 minutes, good stability of calibrator and enzyme label, and low cost. It can meet the clinical needs for auxiliary diagnosis and treatment of acute ischemic brain injury.

The invention relates to a specific protein analyzer sample track sample injection step cycle dilution reexamination method. The method comprises the following steps: 1, sucking a sample to be detected, and respectively adding the sample to be detected into a reaction cup and a dilution cup; 3, judging whether the analyzer outputs an effective detection result or not, if yes, executing the step 6, and if not, executing the step 4; 4, the dilution puncture needle sucks the sample diluent and the to-be-detected sample in the dilution cup and distributes the sample diluent and the to-be-detected sample in the dilution cup to the dilution cup in an idle state for dilution, and the diluted to-be-detected sample is obtained; 5, sucking the diluted to-be-detected sample into the idle reaction cup by the sample adding needle, and executing the step 2; 6, emptying and cleaning the reaction cup and the dilution cup corresponding to the to-be-detected sample, according to the scheme, the dilution and re-detection process of the sample does not need to be manually intervened, when the detection result is not output, the sample can be automatically diluted and re-detected through the dilution puncture needle and the sample adding needle, the re-detection time is greatly shortened, and the detection efficiency is improved.

A corneal tissue exosome collected after rapid culture of a corneoscleral tissue directly following corneal transplantation is disclosed. The overall manufacturing process is simple, eliminating the procedures of thawing, isolation, and cell culture in conventional cell culture processes, and possesses high production yield and homogeneity, while reducing the generation of biomedical waste. The corneal tissue exosome obtained from the corneoscleral tissue exhibits specific protein expression and possesses potential for treating wound repair, ocular diseases, cancer, and immune-related diseases.

Provided herein are compositions of chimeric shuttle-binder-effector fusion proteins with components related to modulating endogenous cytotoxic effector mechanisms, which are useful for therapeutic effects on predetermined target molecules. These shuttle-binder-effector proteins also have specific epitope binding affinities for these target molecules. Compositions for modified cells expressing these chimeric shuttle-binder-effector fusion proteins are also provided. Methods for the modification of cells to express these chimeric shuttle-binder-effector fusion proteins and for delivering the chimeric shuttle-binder-effector fusion proteins into target cells using the lytic granule cellular mechanisms in these modified cells are also provided.

The invention belongs to the technical field of food-borne functional factors, and particularly relates to a bioactive glycopeptide as well as a preparation method and application thereof. According to the application, casein glycomacropeptide is taken as a substrate, specific protease is adopted for carrying out directional enzymolysis reaction on the casein glycomacropeptide, and after primary separation and purification by hydrophilic interaction chromatography and secondary purification by cation exchange chromatography are carried out, the bioactive glycopeptide with the molecular weight of less than 1,500 Da and more than 80% of components and the random coil secondary structure content of more than 35% is obtained. A system performance test shows that in an in-vitro cell experiment, the bioactive glycopeptide prepared by the embodiment of the invention can remarkably improve the proliferation rate of preosteoblasts and lay a sufficient cell quantity foundation for bone cell generation; meanwhile, the activity of an osteogenic early differentiation key marker ALP is effectively up-regulated, and the differentiation process of preosteoblasts towards the osteoblast direction is accelerated; in addition, the expression quantity of osteogenesis-related regulatory protein calcium-sensitive receptors is remarkably increased, and the function improvement of cells to mature bone cells is further promoted.

This application belongs to the field of biotechnology, specifically relating to giant salamander skin collagen peptides, their preparation methods, and applications. This application provides a method for preparing giant salamander skin collagen peptides. The method first pre-treats the fish skin, then performs ultrasonic-assisted extraction under acidic conditions to effectively promote collagen dissolution. The extract undergoes flocculation to remove impurities, significantly reducing interference from other proteins. The enzymatic hydrolysis stage employs a stepwise enzymatic hydrolysis strategy: first, a combination of alkaline protease and another specific protease is used for hydrolysis, sequentially cleaving the complex structure of giant salamander skin collagen to improve initial hydrolysis efficiency and generate specific intermediate peptides; subsequently, a flavor protease is added for further deep hydrolysis to achieve complete hydrolysis. This method has high enzymatic hydrolysis efficiency, controllable hydrolysis degree, concentrated molecular weight distribution of the obtained collagen peptides, high yield of the target product, and stable process.

A method includes steps of: obtaining an original section image that is related to a subject and that includes cell-image portions; for each of the cell-image portions, determining a number of specific protein signals as a specific protein number, determining a number of specific chromosome signals as a specific chromosome number, and calculating a ratio of the specific protein number to the specific chromosome number as an individual protein-to-chromosome ratio; selecting N number of critical cell-image portions from among the cell-image portions according to the individual protein-to-chromosome ratios; and determining a risk of the subject developing breast cancer based on the specific protein number and the specific chromosome number determined for each of the N number of critical cell-image portions.